Article Details

Dimerix (ASX:DXB) receives FDA feedback for DMX-200 trial

Retrieved on: 2021-07-19 07:18:45

Tags for this article:

Click the tags to see associated articles and topics

Dimerix (ASX:DXB) receives FDA feedback for DMX-200 trial. View article details on hiswai:

Excerpt

The ASX-lister said the FDA was "broadly" supportive of its proposed phase three study design and that its advice was generally consistent with ...

Article found on: themarketherald.com.au

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up